Genetically engineered neural stem cells ( NSCs ) therapy for neurological diseases; state‐of‐the‐art
Biotechnology Progress · 2023
DOI: 10.1002/btpr.3363 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biotechnology Progress, 2023. Verfasst von Ghufran Lutfi Ismaeel und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmacy, University of Al-Ameed, Karbala, Iraq. Hauptthemen laut MEDLINE: Neural Stem Cells, Genetic Engineering, Nervous System Diseases, Stem Cell Transplantation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 269 Literaturangaben.
Abstract (Originalsprache)
Neural stem cells (NSCs) are multipotent stem cells with remarkable self‐renewal potential and also unique competencies to differentiate into neurons, astrocytes, and oligodendrocytes (ODCs) and improve the cellular microenvironment. In addition, NSCs secret diversity of mediators, including neurotrophic factors (e.g., BDNF, NGF, GDNF, CNTF, and NT‐3), pro‐angiogenic mediators (e.g., FGF‐2 and VEGF), and anti‐inflammatory biomolecules. Thereby, NSCs transplantation has become a reasonable and effective treatment for various neurodegenerative disorders by their capacity to induce neurogenesis and vasculogenesis and dampen neuroinflammation and oxidative stress. Nonetheless, various drawbacks such as lower migration and survival and less differential capacity to a particular cell lineage concerning the disease pathogenesis hinder their application. Thus, genetic engineering of NSCs before transplantation is recently regarded as an innovative strategy to bypass these hurdles. Indeed, genetically modified NSCs could bring about more favored therapeutic influences post‐transplantation in vivo, making them an excellent option for neurological disease therapy. This review for the first time offers a comprehensive review of the therapeutic capability of genetically modified NSCs rather than naïve NSCs in neurological disease beyond brain tumors and sheds light on the recent progress and prospect in this context.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, College of Pharmacy, University of Al-Ameed, Karbala, Iraq.
- Department of Clinical Laboratory Sciences, College of Pharmacy, University of Al-Ameed, Karbala, Iraq.
- Department of Biochemistry, College of Science, University of Jeddah, Jeddah, Saudi Arabia.
- Department of Radiology and Sonar, College of Medical Techniques, Al-Farahidi University, Baghdad, Iraq.
- Intelligent Medical Systems Department, Al-Mustaqbal University College, Babylon, Iraq.
- Collage of Pharmacy, National University of Science and Technology, Dhi Qar, Iraq.
ORCID-Profile: Haider Abdulkareem Almashhadani
Zitieren
APA
Lutfi Ismaeel, G., Makki AlHassani, O. J., S Alazragi, R., Hussein Ahmed, A., H Mohamed, A., Yasir Jasim, N., Hassan Shari, F., & Almashhadani, H. A. (2023). Genetically engineered neural stem cells ( NSCs ) therapy for neurological diseases; state‐of‐the‐art. Biotechnology Progress. https://doi.org/10.1002/btpr.3363
Vancouver
Lutfi Ismaeel G, Makki AlHassani OJ, S Alazragi R, Hussein Ahmed A, H Mohamed A, Yasir Jasim N, et al. Genetically engineered neural stem cells ( NSCs ) therapy for neurological diseases; state‐of‐the‐art. Biotechnology Progress. 2023. doi:10.1002/btpr.3363
BibTeX
@article{LutfiIsmaeel2023,
author = {Lutfi Ismaeel, Ghufran and Makki AlHassani, Olfet Jabbar and S Alazragi, Reem and Hussein Ahmed, Ammar and H Mohamed, Asma'a and Yasir Jasim, Nisreen and Hassan Shari, Falah and Almashhadani, Haider Abdulkareem},
title = {Genetically engineered neural stem cells ( NSCs ) therapy for neurological diseases; state‐of‐the‐art},
journal = {Biotechnology Progress},
year = {2023},
doi = {10.1002/btpr.3363}
}
EUVIMED